Drug Trial Radar · NCT07424677
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 11, 2026
Primary completion
Jul 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy
Conditions
- Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mgDrug
Saroglitazar magnesium 1 mg once daily, orally each morning before breakfast
PlaceboDrug
Matching Placebo once daily, orally each morning before breakfast
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of participants with ALP ≤ ULN and ≥ 15% decrease from baseline in ALPTime frame: Baseline to Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
US203
Lakewood Rch, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.